Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

CHMP Recommends Approval of Glofitamab Plus Chemotherapy for R/R DLBCL

February 28th 2025

CHMP has recommended glofitamab plus gemcitabine and oxaliplatin for R/R DLBCL.

Targeting Menin: A New Frontier in Treating Refractory Leukemias

February 28th 2025

Incorporation of menin inhibitors is central to improving the outcome of difficult-to-treat leukemias.

Dr Kitko on Clinical Outcomes With Axatilimab According to Prior Lines of Therapy for Chronic GVHD

February 27th 2025

Carrie L. Kitko, MD, discusses outcomes with axatilimab in patients with chronic graft-vs-host-disease according to prior lines of therapy received.

Dr Riedell on the Rationale for Evaluating Rapcabtagene Autoleucel in R/R DLBCL

February 27th 2025

Peter Riedell, MD, highlights the rationale for investigating CAR T-cell therapy rapcabtagene autoleucel in relapsed/refractory DLBCL.

Escalating Lymphodepletion ± Rituximab Before CD19-Directed CAR T-Cell Therapy is Safe in R/R DLBCL

February 27th 2025

Escalating doses of lymphodepleting chemotherapy with or without rituximab prior to CAR T-cell therapy was safe in relapsed/refractory DLBCL.

FDA Accepts Resubmission of BLA for Odronextamab in R/R Follicular Lymphoma

February 26th 2025

The resubmission of a BLA for odronextamab was accepted by the FDA for the treatment of patients with relapsed/refractory follicular lymphoma.

AUTX-703 Receives FDA Fast Track Designation in Relapsed/Refractory AML

February 24th 2025

The FDA has granted the novel, oral KAT2A/B degrader AUTX-703 fast track designation for the treatment of patients with relapsed/refractory AML.

Five Under 5: Top Oncology Videos for the Week of 2/16

February 23rd 2025

The top 5 videos of the week cover insights in prostate cancer, multiple myeloma, RCC, urothelial carcinoma, and LBCL.

Odronextamab Shows Efficacy, Safety in R/R DLBCL After Progression Post–CAR T-Cell Therapy

February 21st 2025

Odronextamab produced durable responses in relapsed/refractory diffuse large B-cell lymphoma after disease progression following CAR T-cell therapy.

Dr Falchi on Long-Term Outcomes of Fixed-Duration Epcoritamab Plus R-CHOP in DLBCL

February 21st 2025

Lorenzo Falchi, MD, discusses the long-term outcomes of fixed-duration epcoritamab plus R-CHOP in previously untreated patients with DLBCL.

Tambiciclib Plus Zanubrutinib Delivers Responses in R/R DLBCL

February 20th 2025

Tambiciclib plus zanubrutinib generated responses in patients with relapsed/refractory diffuse large B-cell lymphoma.

Non-Myeloablative HSCT Regimen Shows Potential for Immune Tolerance in Haploidentical Living Donor Combined Kidney/Hematopoietic Transplant

February 16th 2025

Non-myeloablative HSCT with TLI/TBI/ATG conditioning was safe and active in eliciting immune quiescence and tolerance.

FOXP3/Helios Expression in CD4+ Tcons Correlates With T-Cell Activation After Orca-T in Hematologic Malignancies

February 16th 2025

CD4-, FOXP3-, and Helios-positive conventional T cells were increased in patients receiving Orca-T vs peripheral blood stem cell grafts.

Five Under 5: Top Oncology Videos for the Week of 2/9

February 16th 2025

The top 5 videos of the week cover insights in plexiform neurofibromas, melanoma, myeloma, leukemia, and LBCL.

Orca-T’s Display of Decreased NRM, Increased RFS May Contribute to Favorable OS in Hematologic Malignancies

February 15th 2025

Orca-T improved OS vs post-transplant cyclophosphamide in a retrospective analysis of patients with hematologic malignancies.

The OncFive: Top Oncology Articles for the Week of 2/9

February 15th 2025

Mirdametinib is approved in select plexiform neurofibromas, experts preview top ASCO GU abstracts, NCCN updates ctDNA stance in several tumors, and more.

Orca-Q Shows Promise in High-Risk Hematologic Cancers and BFT Conditioning May Synergize With the Agent

February 14th 2025

One-year follow-up data from an ongoing phase 1 study showed that Orca-Q offered similar benefits as T-cell depletion, without the typical compromises seen.

Axatilimab Displays Durable Responses in cGVHD Irrespective of Number of Prior Lines of Treatment

February 14th 2025

Axatilimab displayed similar efficacy regardless of the number of prior lines of therapy in chronic graft-versus-host disease.

Orca-T With RIC Is Safe in Advanced Hematologic Malignancies

February 14th 2025

Orca-T with reduced-intensity conditioning displayed robust and early donor myeloid and T-cell engraftment in advanced hematologic malignancies.

Axatilimab, Ruxolitinib, and Belumosudil Combo Elicits Responses in Chronic GVHD

February 14th 2025

Favorable responses were demonstrated with the treatment of axatilimab plus ruxolitinib/belumosudil in heavily pretreated patients with chronic GVHD.